Holen Sie sich die Stockscreener-App
18.18
1.31%
0.26
Handel nachbörslich:
18.10
-0.08
-0.44%
Schlusskurs vom Vortag:
$17.92
Offen:
$18.25
24-Stunden-Volumen:
9.87M
Relative Volume:
4.39
Marktkapitalisierung:
$1.90B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-238.77M
KGV:
-0.6782
EPS:
-26.808
Netto-Cashflow:
$-216.62M
1W Leistung:
+86.01%
1M Leistung:
+62.68%
6M Leistung:
+421.70%
1J Leistung:
+136.09%
1-Tages-Spanne:
$17.44
$19.00
1-Wochen-Bereich:
$7.85
$22.30
52-Wochen-Spanne:
$2.7601
$22.30
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
18.18 | 1.87B | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Will Alumis Inc. stock deliver long term returnsChart Signals & Community Consensus Trade Alerts - ulpravda.ru
Will Alumis Inc. stock beat EPS estimatesTrade Ideas & Free Real-Time Volume Trigger Notifications - ulpravda.ru
What's Going On With Alumis Stock Thursday? - Benzinga
Alumis Prices Upsized $300 Million Public Offering of Common Shares - MarketScreener
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Strong Share Price Momentum - Yahoo Finance
Alumis (ALMS) Is Up 83.6% After Phase 3 Psoriasis Win And NDA PlanHas The Bull Case Changed? - simplywall.st
Why a California biotech is selling 17,650,000 new shares to the public - Stock Titan
Alumis prices upsized public offering of common stock at $17 per share - Investing.com
Alumis Inc. Announces Pricing of Upsized Public Offering of 17.65 Million Shares at $17.00 Each - Quiver Quantitative
Alumis Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Alumis announces pricing of upsized public offering of common stock - MarketScreener
Alumis Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewswire Inc.
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies - Yahoo Finance
Should You Chase the Rally in Alumis Stock Today? - Barchart.com
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise (ALMS) - Seeking Alpha
Biopharma firm Alumis extends gains after commencing $175 mln stock offering - TradingView — Track All Markets
Guggenheim raises Alumis stock price target to $32 on positive trial data - Investing.com Nigeria
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential - Stocktwits
Why Alumis Stock Spiked Almost 100% Yesterday - TIKR.com
Alumis stock hits record high as Wall Street cheers phase 3 psoriasis 'win' — analysts see best-in-class potential - MSN
Should You Jump Into the Alumis Stock Rally Now? - Bitget
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | - GuruFocus
Sandisk, Alumis, Micron Technology, Ventyx Biosciences, And Western Digital: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Assessing Alumis (ALMS) Valuation After Positive Envudeucitinib Phase 3 Trial Success - simplywall.st
Alumis plans $175 million common stock offering By Investing.com - Investing.com Nigeria
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - Yahoo Finance
Alumis’ TYK2 envu in view as standout in psoriasis phase III - BioWorld MedTech
Alumis stock nearly doubles on 'truly remarkable' drug trial, plan to seek FDA approval - The Business Journals
Alumis Looks To Come From Behind In TYK2 Race - Citeline News & Insights
Why This J&J Rival Just Catapulted More Than 95% - Investor's Business Daily
Alumis Announces Proposed Public Offering of Common Stock - The Manila Times
Biotech Alumis plans $175M stock sale in new public offering - Stock Titan
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | ALMS Stock News - GuruFocus
Alumis Inc.: Is It Too Late To Buy? - StocksToTrade
Oppenheimer raises Alumis stock price target to $50 on positive trial results - Investing.com UK
Dow Jumps Over 400 Points; US Services Activity Falls In December - Benzinga
Alumis posts late-stage trial successes for TYK2 inhibitor in plaque psoriasis - FirstWord
Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results - Quiver Quantitative
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis soars as TYK2 drug hits mark in psoriasis trials - BioPharma Dive
Alumis (NASDAQ:ALMS) Sets New 12-Month HighWhat's Next? - MarketBeat
Alumis Skin Medication Demonstrates Significant Advantages in Advanced Trials, Shares Surge - Bitget
Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval - Endpoints News
Baird raises Alumis stock price target to $35 on strong psoriasis trial data - Investing.com Nigeria
Alumis Shares Jump as Envudeucitinib Hits Phase III Endpoints in Psoriasis, NDA Planned for 2026 - MarketBeat
Alumis Stock Hits Record High on Psoriasis Drug Trial Results - Schaeffer's Investment Research
Alumis price target raised to $39 from $17 at Wells Fargo - TipRanks
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars - Benzinga
Alumis (ALMS) Stock: Clinical Trial Results Send Shares Up 60% on Tuesday - Blockonomi
Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high - TechStock²
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
| Foresite Capital Management VI | 10% Owner |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| Tananbaum James B. | Director |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| Foresite Labs, LLC | 10% Owner |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| AKKARAJU SRINIVAS | Director |
Nov 20 '25 |
Buy |
7.20 |
125,743 |
905,350 |
643,260 |
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):